Navigation Links
Hope for 14 Million Rosacea Sufferers: Pyratine-XR(TM) Study to be Presented at South Beach Symposium
Date:2/12/2009

NAPA, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a life sciences company engaged in the development of technologies that target the science of healthy aging, announced today that positive study results from a clinical trial of Pyratine-XR(TM) in patients with rosacea will be presented February 13, 2009, at the 7th Annual South Beach Clinical Dermatology Symposium in Miami, Florida.

Dr. Mark Nestor, the Symposium chair, will be presenting "Cytokinins: Cutaneous Aging and Rosacea" at 4:45 PM.

Based on positive results demonstrated in previous studies of Pyratine-6(TM) (0.1% furfuryl tetrahydropyranyladenine) for the remediation of photodamaged skin and erythema, with resulting reduction in facial redness and fine wrinkles in as early as two weeks, Senetek initiated a clinical trial for assessing the effects of Pyratine-XR(TM) (0.125% furfuryl tetrahydropyranyladenine) in improving the clinical signs and symptoms of rosacea.

According to the National Rosacea Society, more than 14 million Americans have rosacea, yet only a small fraction are being treated. The chronic skin disease can affect adults and children of any skin type. While the cause is unknown and there is no cure, scientific advancements are now offering rosacea sufferers hope and a way to control the signs and symptoms of this potentially life-disruptive disorder.

Eighteen subjects with mild-to-moderate rosacea participated in a 48-week study at the University of California, Irvine, and were evaluated through physician assessments of inflammatory lesion count (papules and pustules), severity of erythema (redness) and telangiectasia (spider veins) and overall clinical improvement, as well as through patient assessments of signs and symptoms of rosacea and skin tolerance.

Data suggests that Pyratine-XR(TM) may offer important advantages over currently available treatments for rosacea, primarily oral and topical antibiotics, which involve long-term tolerability and other health concerns. Pyratine-XR(TM) produced a progressive decrease in the symptoms associated with rosacea including redness and lesions. All subject self-assessments showed good tolerability and cosmetic acceptability.

After 48 weeks, there was overall clinical improvement in 80% of subjects, including reduction of erythema and papules. The investigators saw continual, statistically significant mean improvement with Pyratine-XR(TM) treatment, including a 90% improvement in lesions, 45% improvement in erythema and a 28% improvement in telangiectasia. The product was well tolerated, and in an earlier assessment of 24 patients, there was a 41% mean improvement in skin dryness as early as week four, with results continuing to improve over the 48- week period. Pyratine-XR(TM) produced a significant improvement in skin barrier function at weeks 4 through 48 as measured by a decrease in water loss from the skin.

"We are incredibly pleased with the results reported in this rosacea- specific study, with continual improvement in lesions, redness and spider veins. Unlike current therapies, Pyratine-XR(TM) was well tolerated by all patients, and offers hope to a myriad of individuals suffering from facial redness, acne lesions and spider veins, such as those afflicted with eczema, atopic dermatitis and rosacea. We are pleased that the study results are being presented by Dr. Nestor at this prestigious meeting," said Frank J. Massino, Chairman and CEO of Senetek PLC. "The clinical trials are extremely promising, and we anticipate a tremendous physician and patient response to Pyratine- XR(TM), which will officially launch at the American Academy of Dermatology's 67th Annual Meeting in San Francisco, March 6-10, 2009."

About Senetek, PLC

Senetek PLC (OTC Bulletin Board: SNKTY) is a life sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of kinetin, the best-selling anti-aging product sold in the North American physician market. For more information, visit the company's website at http://www.senetekplc.com.

About Dr. Mark S. Nestor

Mark S. Nestor, M.D., Ph.D. is a board-certified dermatologist and dermatologic surgeon, and director of the Center for Cosmetic Enhancement in Aventura, Florida. Dr. Mark Nestor currently serves as President of the American Society for Photodynamic Therapy, and as a Volunteer Associate Professor of the University of Miami, Miller School of Medicine. He is the immediate Past President of the International Society of Cosmetic and Laser Surgeons.


'/>"/>
SOURCE Senetek, PLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Vermillion Presents Critical Data From Its OVA1 Clinical Trial
2. SynergEyes, Inc. Raises $13.3 Million in Series C Financing
3. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
4. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
5. Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
6. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
7. Michael J. Fox Foundation Awards $2.9 Million for Two New Parkinsons Disease Clinical Trials
8. Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinsons Disease Research
9. Micromet Expands Committed Equity Financing Facility to $75 Million
10. German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008
11. Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/5/2017)... 5, 2017  In response to the nationwide ... Maxillofacial Surgeons (AAOMS) released prescribing recommendations that urge ... used as a first-line therapy to manage a ... Recognizing the value and importance ... "Opioid Prescribing: Acute and Postoperative Pain Management" stresses ...
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and Company ... results for the third quarter of 2017 on Tuesday, ... call on that day with the investment community and ... The conference call will begin at 9 a.m. ... access a live webcast of the conference call through ...
(Date:9/28/2017)... WASHINGTON , Sept. 28, 2017 Cohen ... to advance the use of wearable and home sensors ... brain disorders. Early Signal Foundation, a nonprofit organization focused ... populations, will provide an affordable analytical system to record ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... QUEENS, N.Y (PRWEB) , ... October 13, 2017 , ... ... recently became a member of ElderCounsel, a national organization of elder law and special ... constantly changing laws and rules. It also provides a forum to network with elder ...
(Date:10/13/2017)... N.J. (PRWEB) , ... October 13, 2017 , ... The ... Holly Day Market. Featuring a collection of specialty vendors and unique items from across ... personalized and quality-focused health and wellness services offered by the VNA. The boutique ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... of the most popular and least understood books in the Holy Scriptures, Revelation. The ... that have baffled scholars for centuries. Many have tossed it off as mere rubbish, ...
(Date:10/13/2017)... ... , ... “The Journey: From the Mountains to the Mission Field”: the story ... the Philippines. “The Journey: From the Mountains to the Mission Field” is the creation ... has taught all ages and currently teaches a class of ladies at her church, ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
Breaking Medicine News(10 mins):